CARLSBAD, Calif., April 10, 2008 (PRIME NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), a leading medical device company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, will conduct a webcast and conference call with analysts and investors following the release of its first quarter 2008 results on Thursday, April 24, 2008 at 1:30 p.m. PT / 4:30 p.m. ET.
After the close of the market on Thursday, April 24, 2008 and prior to the conference call, Alphatec will distribute a copy of the first quarter 2008 results press release. To listen to the webcast, or to view the press release, please visit the investor relations section of the Alphatec website at www.alphatecspine.com. The dial-in numbers are (877) 681-3375 for domestic callers and (719) 325-4915 for international. A live webcast of the conference call will be available online from the investor relations section of the Company's corporate Web site at www.alphatecspine.com. The webcast will be recorded and will remain available on the investor relations section of Alphatec's website, www.alphatecspine.com, for one year.
About Alphatec
Alphatec Holdings, Inc. (Nasdaq:ATEC) designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Alphatec's broad product portfolio and pipeline includes a variety of spinal implant products and systems focused on solutions addressing the cervical, thoracolumbar, intervertebral, minimally invasive, motion preservation, vertebral compression fractures and allograft markets. Alphatec's "surgeons' culture" emphasizes collaboration with spinal surgeons to conceptualize, design and co-develop a broad range of products. State-of-the-art in-house manufacturing capabilities provide a unique competitive advantage, enabling Alphatec to rapidly deliver customized solutions to meet surgeons' and patients' critical needs. Alphatec has 23 issued U.S. patents, six issued foreign patents and 30 pending patent applications, including 10 pending U.S. applications, six pending international applications and 15 pending foreign national applications. Alphatec's principal product offerings are primarily focused on the global spine implant and biologics market, which is estimated to be more than $7.0 billion in 2007. In addition to its U.S. operations, Alphatec also markets a range of spine and orthopedic products in Asia through its subsidiary, Alphatec Pacific, Inc. For more information, please visit www.alphatecspine.com.
The Alphatec Holdings, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3520